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ABSTRACT
Stenotrophomonas maltophilia is an aerobic, oxidase-negative and catalase-positive bacillus. S. mal-
tophilia is a recognized opportunistic pathogen. Due to the advancements in invasive medical pro-
cedures, organ transplantation and chemotherapy of malignant illnesses, the relevance of this
pathogen increased significantly. The therapy of S. maltophilia infections is challenging, as these
bacteria show intrinsic resistance to multiple classes of antibiotics, the first-choice drug is sulfa-
methoxazole/trimethoprim. Our aim was to assess the epidemiology of S. maltophilia from various
clinical samples and the characterization of resistance-levels and resistotyping of these samples over a
long surveillance period. The study included S. maltophilia bacterial isolates from blood culture
samples, respiratory samples and urine samples and the data for the samples, received between
January 2008 until December 2017, a total of 817 S. maltophilia isolates were identified (respiratory
samples n 5 579, 70.9%, blood culture samples n 5 175, 21.4% and urine samples n 5 63, 7.7%).
Levofloxacin and colistin-susceptibility rates were the highest (92.2%; n 5 753), followed by tige-
cycline (90.5%, n 5 739), the first-line agent sulfamethoxazole/trimethoprim (87.4%, n 5 714), while
phenotypic resistance rate was highest for amikacin (72.5% of isolates were resistant, n 5 592). The
clinical problem of sulfamethoxazole/trimethoprim-resistance is a complex issue, because there is no
guideline available for the therapy of these infections.
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INTRODUCTION
Antimicrobial resistance (AMR) in Gram-negative bacteria is a major public health concern,
severely limiting therapeutic options in clinical settings [1]. While the emergence of plasmid-
mediated resistance to extended-spectrum cephalosporins (due to AmpC- and extended-
spectrum-b-lactamases) [2, 3], carbapenems (due to serine- and metallo-b-lactamases) [4],
and colistin in the members of the Enterobacterales order (predominantly in Klebsiella
pneumoniae) has taken center-stage in the last few years [5], the clinical problem of infections
due to drug resistant non-fermenting Gram-negative bacteria (NFGNB) has been recognized
since the beginning of the 21st century [6]. NFGNB are a taxonomically-heterogenous group,
including (in decreasing frequency of isolation) Pseudomonas aeruginosa, Acinetobacter spp.,
Stenotrophomonas maltophilia, Burkholderia cepacia complex, Elizabethkingia meningosep-
tica, Sphingomonas paucimobilis, Alcaligenes faecalis, Achromobacter xylosoxidans and
Chryseobacterium indologenes among others [7]. All NFGNB are characterized by their
ubiquitous nature in aquatic environments and in the soil (frequently associated with plants);
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due to their adaptability and tenacity, they are also impor-
tant nosocomial pathogens, found in ventilator machines
and other equipments used for invasive procedures, in
addition to water taps, humidifiers or mattress covers in
hospital wards [7, 8].
S. maltophilia (previously Xanthomonas maltophilia) is
an aerobic, oxidase-negative and catalase-positive bacillus,
which is the principal human pathogen of the genus,
currently consisting of 16 different species [9]. In publica-
tions before the 1980's, S. maltophilia was reported as an
infrequently isolated microorganism from clinical samples,
mostly from hospital-acquired infections. Nevertheless, due
to the advancements in invasive medical procedures, organ
transplantation and chemotherapy of malignant illnesses,
the relevance of this pathogen increased significantly since
the 2000's (in correlation with the increased number of
patients at risk to develop infections by bacteria with low
virulence) [10]. S. maltophilia is a recognized opportunistic
pathogen. The incidence of S. maltophilia infections in
nosocomial settings is reported to be around 7–38 cases/
10,000 discharges, and it is a frequent cause of outbreaks at
intensive care units; in addition, increasing amount of re-
ports highlight the role of these bacteria in community-ac-
quired infections as well [11, 12]. The main clinical
manifestations of S. maltophilia infections are respiratory
infections (i.e., tracheobronchitis) and bacteremia, however,
infections from almost all anatomical regions have been
described (e.g., meningitis, skin and soft tissue infections,
genitourinary infections) [13, 14]. The crude mortality rate
for invasive S. maltophilia infections is quite high, especially
if the patients receive inappropriate empiric therapy: 20–
60% in case of bacteremia/sepsis and 20–70% in case of
pneumonia [15, 16]. The colonization of cystic fibrosis pa-
tients with S. maltophilia has also been extensively described,
often leading to more frequent exacerbations and worse
outcomes [17].
The therapy of S. maltophilia infections is challenging, as
these bacteria show intrinsic resistance to multiple classes of
antibiotics [9]. From a clinical perspective, resistance against
b-lactam antibiotics (most notably, the carbapenem group)
is a major concern; this is conferred by two zinc-dependent,
chromosomally mediated b-lactamases (L1 and L2) [14, 18].
In addition, a resistant phenotype may be expressed through
a multitude of other mechanisms, e.g., lipopolysaccharide-
changes or modifying enzymes for aminoglycosides, or
through the over-expression of energy-dependent efflux
pumps (e.g., SmeDEF, SmeVWX, SmeYZ), affecting sus-
ceptibility to several drugs [19]. Based on clinical experi-
ences and current recommendations, the first-choice drug
for the therapy of S. maltophilia infections is sulfamethox-
azole/trimethoprim (or co-trimoxazole; 15 mg kg1 day1)
[12, 14]. Additionally, a recent meta-analysis has concluded
that the use of levofloxacin in these infections is non-inferior
to sulfamethoxazole/trimethoprim [20]. Nonetheless, in
certain clinical situations (hypersensitivity to the drug,
vulnerable patient population to fluoroquinolones) and in
case of resistance to these agents, alternative drugs must be
considered, usually in combination: these antibiotics include
the tetracyclines (doxycycline, minocycline, and tigecycline),
some remaining b-lactams with retained activity (ticarcillin/
clavulanate, ceftazidime), colistin, rifampin and chloram-
phenicol [9, 12, 14]. Resistance to the first-line agent sulfa-
methoxazole/trimethoprim is around 2–10% in Western
Europe and in the US, however, resistance rates as high as
30–48% were reported from the Far East (China, Taiwan)
[21]; resistance levels are generally higher in colonizer
strains from cystic fibrosis patients (20–80%) [22]. Multi-
drug resistant (MDR) and extensively drug resistant (XDR)
strains of S. maltophilia are concerning from both thera-
peutic and infection control perspectives, thus, the World
Health Organization listed this pathogen as a “priority
pathogen” for pharmaceutical companies to incentivize
development of novel antibiotics [23].
Several surveillance studies have been published on the
epidemiology of this pathogen, however, these epidemio-
logical trends and resistance levels vary greatly in each
hospital and geographical region; while the knowledge of
local data is necessary to reflect on the regional/national
situation and to allow for the appropriate choice of therapy
[24]. In the present study, our aim was to assess the
epidemiology of S. maltophilia from various clinical samples
and the characterization of resistance-levels in these samples
over a long surveillance period in a tertiary-care teaching
hospital in Southern Hungary.
MATERIALS AND METHODS
Clinical center
The present retrospective microbiological study was carried
out at the Albert Szent-Gy€orgyi Clinical Center, a tertiary-
care teaching hospital in Szeged, Hungary. The study
included S. maltophilia bacterial isolates from blood culture
samples, respiratory samples and urine samples and the data
for the samples from all outpatient Clinics and impatient
departments, corresponding to the time period between
January 2008 until December 2017. Bacterial isolates were
considered separate if they were detected more than 14 days
apart, or S. maltophilia isolates with different antibiotic
susceptibilities were isolated [12]. Isolates collected for sur-
veillance/infection control purposes from hospital environ-
ments were excluded from the analysis.
Sample processing and bacterial identification
Blood culture samples, respiratory samples and urine sam-
ples were processed in the Institute in accordance with in-
ternational guidelines in routine bacteriology. Between 2008
and 2012, the BD Bactec (Beckton Dickinson, Franklin
Lakes, NJ, USA) automated blood culture system was
employed in the Institute, while from 2013 onwards, the
BacT/ALERT 3D (bioMerieux, Marcy-l'Etoile, France)
detection system was utilized. Blood culture bottles were
incubated for 5 days (21 days, if endocarditis was suspected).
Samples were cultured on blood agar, chocolate agar, eosine-
methylene blue or UriSelect agar (in case of urine samples)
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plates (agar plates purchased from Bio-Rad, Berkeley, CA,
USA). Culture plates were incubated at 37 8C for 24–48 h,
aerobically. Between 2008 and 2012, phenotypic methods
and VITEK 2 Compact ID/AST (bioMerieux, Marcy-l’Etoile,
France) were used, while following 2012, matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS; Bruker Daltonics, Bremen, Germany)
was introduced to the diagnostic workflow of the laboratory.
Sample preparation methods and the technical specifications
for MALDI-TOF MS measurements were described else-
where [25].
Antimicrobial susceptibility testing, resistotyping
Susceptibility-testing of S. maltophilia isolates were carried
out using the following methods and protocols: i) sulfa-
methoxazole/trimethoprim susceptibility testing was carried
out using E-tests (Liofilchem, Abruzzo, Italy) on Mueller-
Hinton agar plates, based on EUCAST breakpoints (http://
www.eucast.org; MIC ≤ 4 mg L1 reported as susceptible);
ii) levofloxacin susceptibility testing was performed using E-
tests (Liofilchem, Abruzzo, Italy) on Mueller-Hinton agar
plates, based on CLSI breakpoints (MIC ≤ 2 mg L1 re-
ported as susceptible); iii) amikacin susceptibility testing was
based on a P. aeruginosa-specific breakpoint using E-tests
(Liofilchem, Abruzzo, Italy) on Mueller-Hinton agar plates
(MIC ≤ 16 mg L1 reported as susceptible) [12]; iv) colistin
susceptibility testing was based on a P. aeruginosa-specific
breakpoint using broth microdilution in cation-adjusted
Mueller-Hinton broth (MERLIN Diagnostika, Bornheim-
Hersel, Germany) (MIC ≤ 4 mg L1 reported as susceptible)
[12]; v) tigecycline susceptibility-testing was carried out
using E-tests (Liofilchem, Abruzzo, Italy) on Mueller-Hin-
ton agar plates, the interpretation of results was carried out
using non-species specific (NSS) breakpoints (MIC ≤ 0.25
mg L1 reported as susceptible) [12]. Classification of the
isolates as a multidrug resistant (MDR) or extensively drug
resistant (XDR) was based on the EUCAST Expert Rules
[26]. Resistotypes from the respective susceptibility-results
were defined based on criteria described previously [27, 28].
Staphylococcus aureus ATCC 29213, Enterococcus faecalis
ATCC 29212, Escherichia coli ATCC 25922, P. aeruginosa
ATCC 27853 and S. maltophilia ATCC 13637 were used as
quality control strains.
Statistical analysis
Descriptive statistical analysis was performed using Micro-
soft Excel 2013 (Redmond, WA, Microsoft Corp.). Addi-
tional statistical analyses were performed with SPSS software
version 24 (IBM SPSS Statistics for Windows 24.0, IBM
Corp. Armonk, NY, USA), using the c2-test and two-sam-
ple-test (isolation frequency and resistance trends). P values
<0.05 were considered statistically significant.
Ethics
The study was deemed exempt from ethics review by the
Institutional Review Board of the University of Szeged and
informed consent was not required, as patient data was not
collected and data anonymity was maintained.
RESULTS
Isolation frequency of S. maltophilia
During the 10-year period, a total of 817 S. maltophilia
isolates were identified (81.7 ± 31.0 year1, highest in 2015,
lowest in 2008). The distribution of the samples of origin
was the following: respiratory samples n 5 579 (70.9%),
blood culture samples n 5 175 (21.4%) and urine samples
n 5 63 (7.7%). A pronounced increase was observed in the
isolation frequency of S. maltophilia isolates between two 5-
year periods of the study (2008–2012: n 5 263, 2013–2017:
n 5 554; P 5 0.0011). The majority of isolates originated
from samples sent from inpatients (n 5 694, 84.9%). Isolates
originated from the Intensive Care Units (ICUs; 41.9%; n 5
334), Department of Internal Medicine (29.5%; n 5 241),
Department of Pediatrics (10.1%; n 5 74), Department
of Otorhinolaryngology and Head-Neck Surgery (6.4%;
n 5 52), Department of Oncology (4.7%; n 5 38),
Department of Surgery (4.0%; n 5 33), Department of
Neurology (1.5%; n 5 13) and others (n 5 17; 1.8%).
Antibiotic resistance and resistotypes of S. maltophilia
Out of the tested antibiotics, levofloxacin and colistin-sus-
ceptibility rates were the highest (92.2%; n 5 753), followed
by tigecycline (90.5%, n 5 739), the first-line agent sulfa-
methoxazole/trimethoprim (87.4%, n 5 714), while pheno-
typic resistance was most frequently observed for amikacin
(72.5% of isolates were resistant, n 5 592). 24.1% (n 5 197)
of isolates were fully susceptible to all five tested agents.
Resistance to sulfamethoxazole/trimethoprim occurred
more frequently in the second half of the study period (66 vs.
37; P 5 0.047), while such trends were not observed for the
other antibiotics. Similarly, sulfamethoxazole/trimethoprim-
resistance was also detected more frequently from inpatient
samples (P 5 0.004). MIC ranges for the respective
antibiotics were the following: MICsulfamethoxazole/trimethoprim
5 0.064–32 mg L1, MIClevofloxacin 5 0.25–16 mg L
1,
MICamikacin 5 2–512 mg L
1, MICcolistin 5 0.5–512 mg L
1
and MICtigecycline 5 0.064–8 mg L
1.
The distribution of isolates into various resistotypes is
shown in Table 1.; Type 0 represents fully-susceptible iso-
lates (24.1%), Type I includes isolates resistant to amikacin
or tigecycline only (65.4%), while Type II (1.8%) and Type III
(4.0%) introduces resistance to sulfamethoxazole/trimetho-
prim and levofloxacin, respectively. Type IV (7.0%) repre-
sents resistance to three, while Type V (1.0%) represents
resistance to four individual antibiotics. Type VI (2.2%)
encompasses strains showing resistance to all tested agents.
Based on EUCAST Expert Rules, isolates in Type IV and V
categories also represent MDR S. maltophilia isolates, while
isolates in the Type VI category should be considered XDR.
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DISCUSSION
The aim of our present study was to characterize the resistance
levels of S. maltophilia in a tertiary-care teaching hospital in
the southern region of Hungary over a long surveillance
period using phenotypic methods. S. maltophilia is an
emerging, opportunistic pathogen with low levels of inva-
siveness, mainly affecting severely debilitated patients [29].
The following risk groups have been identified based on the
literature: ICU patients or patient with a long hospital stay,
extensive surgeries, immunosuppressive therapy or acquired
immunosuppression (e.g., HIV-infection, severe neutropenia),
mechanical ventilation, dialysis, patients with chronic illnesses
(e.g., diabetes, respiratory disorders) or cancer, or a develop-
mental abnormality [30]. Prevention of S. maltophilia acqui-
sition and infection is very important from an infection
control point-of-view, in addition to controlling antibiotic
consumption for reducing the emergence of resistant strains
[31]. Extensive use of carbapenems (both on a patient-level
and institutional-level) has also been described as a potential
risk factor for these infections (due to the selection pressure)
[32]. The gastrointestinal tract, infected central venous cath-
eters and the colonized/infected lungs were described as
sources of infection, leading to invasive disease [33]. Due to its
limited invasiveness, S. maltophilia must somehow bypass
natural host defenses to cause illness; nonetheless, virulence
factors, such as biofilm-formation (important for survival on
abiotic surfaces), a positively charged cell surface and fimbriae
are all considered important during the pathogenesis of
these infections [34]. Previously it was hypothesized that S.
maltophilia infections are characterized by the lack of an in-
flammatory response, however, this dogma has been recently
challenged in a murine model, where it was shown that airway
epithelial cells and macrophages react with an increased
expression of IL-8 and TNF-a [35].
Empiric therapy of S. maltophilia infections is sulfa-
methoxazole/trimethoprim, combined with levofloxacin or
ticarcillin/clavulanate (if available); the therapeutic protocol
should be revised after the susceptibility results are available
[1, 2, 12, 14]. Resistance rates to sulfamethoxazole/trimeth-
oprim (12.6%) was higher than the range of resistance in
Western European countries (2–10%), although outlier
countries with higher resistance (e.g., Spain: 25–27%,
Turkey: 10–15%) have already been noted [36, 37]. In
contrast, the low level of levofloxacin resistance is an ad-
vantageous development, as it seems that there is no relevant
difference in the clinical efficacy of these two drugs [20]. The
relevance of the other three tested agents in clinical situa-
tions is harder to ascertain, as there are no evidence or
clinical trials correlating their efficacy in the therapy of S.
maltophilia infections [38]. In addition (as demonstrated in
the Methods section), there are also contradictory infor-
mation regarding susceptibility-testing method for these
bacteria: based on EUCAST, disk diffusion is only available
for sulfamethoxazole/trimethoprim, while CLSI offers disk
diffusion testing breakpoints for levofloxacin and minocy-
cline as well [12, 14, 39]. Some drugs, not even MIC
breakpoints are available (thus, clinical microbiologists
should not interpret them as susceptible or resistant for the
treating physicians), as the pharmacokinetic/pharmacody-
namic attributes, outcomes and antimicrobial efficacy of
these antibiotics have not been characterized in relation with
S. maltophilia infections [12, 14, 39]. The clinical problem of
sulfamethoxazole/trimethoprim-resistance (mediated by the
sul1-sul3 genes) is a complex issue. Because there is no
guideline available for the therapy of these infections, cli-
nicians often act upon national and/or institutional guide-
lines [40]. The development of guidelines would require
reliable data from multiple clinical trials utilizing antibiotics
other than sulfamethoxazole/trimethoprim, with clearly-
defined case definitions and clinical endpoints; unfortu-
nately, such data is currently not available [39, 40].
The definition of resistotyping is the grouping of bacte-
rial isolates by resistance patterns to a set of arbitrarily
chosen antibiotics that are characteristic to specific strains
by phenotypic methods; resistotyping is mainly used for
epidemiological purposes [41]. Although data has been
generated on the resistance-levels of S. maltophilia in other
Table 1. Distribution of various resistotypes among S. maltophilia (2008–2017)
Resistotype Sulfamethoxazole/trimethoprim Levofloxacin Amikacin Tigecycline Colistin
Number of
isolates
0 S S S S S n 5 197 (24.1%)
I-A S S R S S n 5 489 (59.9%)
I-B S S S R S n 5 45 (5.5%)
II-A R S S S S n 5 10 (1.2%)
II-B R S R S S n 5 6 (0.5%)
III-A S R S S S n 5 20 (2.4%)
III-B S R R S S n 5 13 (1.6%)
IV-A R R R S S n 5 5 (0.6%)
IV-B R S R R S n 5 11 (1.3%)
IV-C R S R S R n 5 42 (5.1%)
V-A R R R R S n 5 4 (0.5%)
V-B R R R S R n 5 4 (0.5%)
VI R R R R R n 5 18 (2.2%)
S: susceptible; R: resistant.
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regions of Hungary (where the reported susceptibility to
sulfamethoxazole/trimethoprim higher than in the present
study [99%], in contrast, susceptibility to levofloxacin [75%],
tigecycline [12%] and colistin [9%] were reported to be
much lower [39]), resistotyping for this pathogen has not
been previously described locally or in any other studies
published previously. To highlight their importance, resis-
totypes may be correlated with clinical-therapeutic de-
cisions: e.g., resistotypes 0, IA and IB are pan-susceptible, or
resistant only to ancillary antibiotics, thus, the first-line drug
(sulfamethoxazole/trimethoprim alone or in combination)
may be used without difficulty, if the underlying conditions
or the patient’s medical history allows for it. Resistotypes IIA
and IIB are resistant to sulfamethoxazole/trimethoprim, but
susceptible to levofloxacin, which is presumably just as
clinically-effective as the first-line drug; depending on the
age of the patient, this drug may be clinically used alone or
in combination (with ticarcillin/clavulanate, ceftazidime or
rifampin). Resistotypes IIIA and IIIB are resistant to the
tested fluoroquinolone drug, but susceptible to sulfameth-
oxazole/trimethoprim, corresponding to a similar thera-
peutic approach like resistotypes 0, IA and IB. Therapy of
these infections becomes especially problematic starting
from the IVA resistotype all the way onto resistotype VI,
where, in addition to resistance against sulfamethoxazole/
trimethoprim and/or levofloxacin, the utility of possible
secondary antibiotics is also narrowing: resistance to ami-
kacin, tigecycline and colistin means that only very few
antibiotics are left for therapy and for most of these agents,
clinical evidence of efficacy is limited to case reports [42].
The relevance of amikacin is often questioned, as resis-
tance may quickly develop due to membrane impermeability
or alterations in the bacterial LPS, while colistin is considered
as one of the last-resort agents, due to its nephrotoxic and
neurotoxic adverse events and difficult dosing [43, 44].
Several reports highlight the efficacy of tetracycline-de-
rivatives, especially minocycline as a potential therapeutic
alternative for resistant S. maltophilia infections, demon-
strating high cure rates and advantageous outcomes. How-
ever, the adverse effect-profile of these drugs and the low
serum concentrations achieved by tigecycline should also be
taken into consideration [45]. Besides this, concerns have
been raised that the frequent use of minocycline for the
therapy of Acinetobacter calcoaceticus-baumannii complex
may lead to the emergence of resistance in S. maltophilia [46].
The following limitations of the study should be noted: i)
as the clinical data of the individual patients affected could
not be accessed, the correlation between the symptoms and
the isolation of S. maltophilia is unknown; thus, all true
pathogens and colonizers were included in this study; ii)
resistance of these isolates were characterized only pheno-
typically, the genetic nature of these resistance-determinants
were not detected using molecular biological methods; iii)
minocycline susceptibility-testing was not performed as this
drug is not licensed or available in Hungary; iv) referral/
selection bias as the clinical center is a tertiary-care,
specialized hospital.
CONCLUSIONS
S. maltophilia is an emerging opportunistic pathogen pre-
dominantly isolated from blood culture and respiratory tract
samples, most often causing bacteremia, tracheobronchitis
and soft tissue infections in hospitalized, immunocompro-
mised patients. It is often difficult to distinguish between
colonization and true infection, if the bacteria have been
isolates from non-sterile body sites, however, the surveil-
lance of colonizers is also relevant as in most cases, these
microorganisms will initiate infections in susceptible hosts.
The pharmacotherapy of S. maltophilia infections is limited
by high-level intrinsic resistance, which is often worsened by
acquired non-susceptibility. In our study, 87.4 and 90.5% of
isolates were susceptible to sulfamethoxazole/trimethoprim
and levofloxacin, respectively; in these cases, first-line agents
are appropriate for use, bearing in mind the adverse events
and contraindications associated with these drugs for spe-
cific patient groups. On the other hand, 8.0% were MDR and
2.2% was to be considered XDR strains. Thus, clinical
management of infections, where – for whatever reason –
none of the first-line agents are available for use, depends on
the susceptibility of the pathogen to ancillary agents and the
availability of these antibiotics on an institutional/regional/
national level. Additionally, more studies are needed to
adequately assess the relevance of such antibiotics (i.e.,
colistin, minocycline, tigecycline, amikacin, rifampin, ticar-
cillin/clavulanate or ceftazidime) in the management of
resistant S. maltophilia.
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